enGene Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.7%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.73next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Pre-BLA Meeting with the FDA | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
LEGEND Trial Cohort 1 12-Month Complete Response (CR) Rate Annually25.0%Target: >= 30%
Cash, Cash Equivalents, and Marketable Securities Quarterly285.2MTarget: Sufficient to fund operations into 2H 2028
Watch Items
- FDA Pre-BLA Meeting and BLA Submission InitiationTrigger: Meeting scheduled and BLA filing initiated in 2H 2026Action: Engage with FDA to align on the clinical package and begin rolling BLA submission for detalimogene voraplasmid.
- LEGEND Detalimogene plus Surfactant Cohort Enrollment and EfficacyTrigger: Initial efficacy data from polidocanol surfactant rinse cohortAction: Evaluate if the addition of a surfactant bladder rinse improves the 12-month durability and complete response rates to close the efficacy gap with competitors.
Research as of 24 Jul 2026